secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuBase Therapeutics, Inc. (—)
CIK:        0001173281
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001104659-25-001664
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuBase approves $0.13/share initial distribution in liquidation; CEO/CFO resigns, board change
--------------------------------------------------------------------------------

- Todd Branning resigns as Interim CEO and CFO effective Jan 3, 2025; appointed to Board on Jan 4.
- Dov Goldstein resigns from Board effective immediately on Jan 4, 2025.
- Board approved Plan of Distribution: initial distribution of ~$500,000 ($0.13 per share) to stockholders of record June 26, 2024.
- Company is in process of dissolution; shares delisted from Nasdaq in May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/0001104659-25-001664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/tm252159d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-001664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer